The apoptosis and mitochondrial dysfunction phenotype observed in ezetimibe-treated CRC cells was partially reversed by the mTOR activator, MHY1485 (Figure 5), indicating that ezetimibe induces cell death and mitochondrial dysfunction in CRC cells through the mTOR signaling pathway. The gene discussed is MTOR; the disease is colorectal carcinoma.